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A 54-year-old male with history of anemia and rheumatoid arthritis presented with a three-month history of dyspnea on exertion
and lower extremity edema. Patient was referred for a transthoracic echocardiogram that revealed a large right atrial mass with
reduced ejection fraction of 40% and an incidental large liver mass. Subsequent cardiac MRI revealed a lobulated right atrial mass
measuring 5.4 cm × 5.3 cm with inferior vena cava compression and adjacent multiple large liver lesions confirmed to be malignant
melanoma through biopsy. Interestingly, no primaries were found in the patient. PET/CT imaging displayed hypermetabolicmasses
within the right atrium and liver that likely representmetastases, as well as bilateral pleural effusions,most likely due to heart failure.
Preoperative coronary angiogram demonstrated perfusion to the mass by a dense network of neovasculature arising from the mid
right coronary artery. The cardiac melanoma was surgically removed, and the right atrium was reconstructed with a pericardial
patch. After surgery, all cardiac chambers appeared normal in size and function with associated moderate tricuspid regurgitation.
The patient is currently being administered ipilimumab for systemic therapy of metastatic melanoma.
1. Introduction
Among all possible tumors of the heart, cardiac metastases
most frequently involve melanoma.Though melanoma is the
most frequent cause, cardiac metastases are still considered a
rare event. In a series of 70 autopsies of patients suffering from
metastaticmelanoma, the frequency ofmetastasis to the heart
was 50–71% [1]. However, cardiac metastases were diagnosed
in less than 1% of cases due to asymptomatic presentation in
the majority of these patients [1]. Patients where a cardiac
metastasis is discovered antemortem often present foremost
with symptoms of metastasis in other areas, most commonly
gastrointestinal [2, 3]. When cardiac symptoms are signifi-
cant, surgical intervention can be utilized to improve cardiac
function and prevent further life-threatening complications
such as heart failure, arrhythmias, or tumor embolization
from occurring. Occasionally, melanoma metastases can
present without a primary lesion. In a study of melanomas
of unknown primaries (MUP), 65 of 2485 (2.6%) patients
diagnosed with melanoma were lacking a primary lesion [4].
With our patient, we present a rare case of cardiac and liver
melanoma metastases with an unknown primary tumor.
2. Case Report
A 54-year-old male with history of anemia and rheumatoid
arthritis had noted increased lower extremity edema, chronic
cough, and shortness of breath for 3 months, at which
point his rheumatologist treated him for pneumonia. With
symptoms worsening, the patient visited a primary care
physician, as his father had a history of coronary artery
disease, colon cancer, andmultiple basal cell skin cancers.The
patient was then referred for a transthoracic echocardiogram
(TTE), which revealed a large right atrial mass with reduced
ejection fraction of 40% along with incidental lesions in
the liver. A cardiac MRI and MRI of the abdomen/pelvis
confirmed these results, revealing a lobulated right atrialmass
measuring 5.4 cm × 5.3 cm with inferior vena cava (IVC)
compression and adjacent multiple large liver lesions, the
largest of which measured 6.6 cm × 7.0 cm × 7.3 cm. The
cardiac mass appeared to extend through the right atrial
wall and into the pericardium. The patient’s abdominal MRI
showed mass effect on the bile duct with central biliary
duct dilatation as well as mass effect on the hepatic portal
veins. Mass effect was also seen on the first portion of
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Figure 1: PET/CT scan displayingmetastatic masses in right atrium
and liver, as well as bilateral pleural effusion due to heart failure.
the duodenum causing gastric distention. After completion
of both MRIs, subsequent ultrasound-guided liver biopsy
returned the results of melanoma. Further workup revealed
no cutaneous melanoma lesions. An eye examination was
performed in order to exclude ocular melanoma. Based on
the recent diagnosis of melanoma, the patient was scheduled
to meet with his oncologist 4 weeks later in order to
discuss treatment options. Three days prior to the patient’s
scheduled visit with his oncologist, the patient presented
to the emergency department (ED) with worsening dys-
pnea and lower extremity edema. PET/CT imaging using
F-18 fluorodeoxyglucose (FDG) was conducted for tumor
anatomical localization. The scans displayed hypermetabolic
masses within the right atrium and liver that are consistent
with metastatic disease, as well as bilateral pleural effu-
sions, likely secondary to resultant heart failure (Figure 1).
Preoperative coronary angiogram demonstrated perfusion
to the mass by a dense network of neovasculature arising
from the mid right coronary artery (Figure 2). The cardiac
mass was surgically removed, and the right atrium was
reconstructed with a pericardial patch (Figure 3). Pathologic
analysis of the mass confirmed melanoma. After surgery, all
cardiac chambers appeared normal in size and function with
associated moderate tricuspid regurgitation. Beginning one
month after surgery, the patient was treated for systemic
therapy with four cycles of ipilimumab, 3mg/kg every three
weeks. He subsequently developed autoimmune nephritis
and a significant nephrotic syndrome as well as anasarca but
recovered with pulse steroid therapy within four weeks. He
had an objective response to ipilimumab in the liver and no
recurrence in the heart; however, he developed progression
into the peritoneal cavity, for which he is now being treated
with pembrolizumab, 3mg/kg every three weeks.
3. Discussion
While the skin is the most common location of a primary
lesion, malignant melanomas can also be found on the
mucous membranes, upper esophagus, anus, eyes, or menin-
ges. In the present study, no primary sites were identified;
rather, metastatic melanoma was diagnosed by the presence
of lesions incidentally discovered on the liver and heart.
While primary tumors of the heart are rare, melanomas
Figure 2: Angiogram demonstrating perfusion to the mass by
a dense network of neovasculature arising from the mid right
coronary artery.
Figure 3: Macroscopic view of the cardiac metastatic melanoma
surgically removed from the right atrium.
have a strong tendency to metastasize to the heart, more
commonly to the right atrium [5]. It is typical for metastases
to invade the myocardium and pericardium and, more
rarely, the endocardium [6]. Cardiac metastasis is rarely
the initial manifestation; as many as 1% of patients’ cardiac
melanoma metastases go unrecognized antemortem [5].
These melanomas canmetastasize to the heart through either
lymphatic, hematogenous, direct extension, or intravenous
extension pathways [7].
Clinical symptoms of cardiac metastasis manifest
depending on the location of the metastasis and its resulting
obstruction. Congestive heart failure, dysrhythmia, heart
murmurs, and pericardial effusion are some of the common
resulting symptoms [6, 8]. Reduction of such symptoms and
prevention of further life-threatening complications as well
as potential tumor embolization are driving factors in the
decision to surgically resect cardiac metastases [9]. However,
surgical intervention as treatment for cardiac metastases is
considered palliative rather than curative [10]. Just as clinical
symptoms rely on tumor location, location of the metastases
in the heart also determines the efficacy of surgical treatment.
In our example, the size and location of the patient’s cardiac
melanomawas causing IVC compression. Due to the patient’s
presenting symptoms of dyspnea and lower extremity edema,
surgical resection was considered a priority.
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Cardiacmelanomas have been reported to show response
to treatment when diagnosed early and aggressively. Treat-
ment can often be divided into two modalities—medical and
surgical therapy. A number of surgical resections of cardiac
melanomas have been reported as successful [6, 11]. Similar
reports have shown an improvement in quality of life and
reduction of symptoms for at least 1 year after resection
of cardiac metastases [6, 12]. However, long-term results
regarding resection of cardiac metastases have yet to be
evaluated, as this requires longitudinal data that is not yet
present [10].
Due to this lack of data, a conventional plan for treatment
has not yet been established [6]. Surgery is considered when
palliative treatment is necessary and feasible, such as when
location of metastases significantly impairs organ function
and clear margins are attainable, as demonstrated by our
patient.Medically, often in conjunctionwith surgical therapy,
chemotherapy is the standard form of treatment. Previously,
dacarbazine was the single FDA approved treatment for
metastaticmelanoma. In recent years, ipilimumab and vemu-
rafenib have been successful in Phase 3 clinical trials of
metastatic melanoma and have been used in practice since
their FDA approval [10]. In one study, patients receiving
ipilimumab alone had a median overall survival of 10.1
months (95% CI) compared to the 6.4 months (95% CI) of
those treated with gp100 alone, a well-studied cancer vaccine
inducing immune response [13]. Further, the reduction in the
risk of melanoma progression was 36% for ipilimumab alone
compared to that of gp100 alone or gp100 plus ipilimumab
[13]. Based on these positive Phase 3 trial results, the patient
was started on ipilimumab to treat metastatic melanoma.
As the liver lesions were considered inoperable, ipilimumab
was utilized as first-line therapy for the treatment of this
particularly advanced melanoma.
The case presented is unique in that liver and cardiac
metastases were found with no primary lesion. In a study
mentioned previously, 65 of 2485 (2.6%) patients with meta-
static melanoma presented without a primary lesion, making
this a rare occurrence. A hypothesis regarding the origin of
an MUP describes that a primary lesion can regress inciden-
tally. Comparable patterns of the progression of metastatic
melanoma with and without known primaries provide sup-
port for this theory [14]. Regression of primary melanoma
could possibly be due to a forceful immune response by
the host [4]. An alternative hypothesis suggests that ectopic
melanocytes may have been trapped in lymph nodes or
other organs inhibiting the formation of a primary lesion.
This theory arises from evidence that in certain occasions
benign melanocytes have been shown to reside in lymph
nodes [4]. An additional theory suggests that melanocytes or
melanocyte-like cells can reside in the heart [15]. It is possible
in this case that a primary melanoma could have arisen from
such a population [15].
With the progression of novel systemic therapies, com-
bined with the potential benefit of surgery, outcomes for
patients with cardiac melanoma metastasis are advancing.
Surgery will continue to be considered an indispensable
option, as it has the possibility of providing successful
palliative care.
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